Expression of oestrogen receptor beta (ER beta) occurs in multiple cell types, including some germ cells, in the rat testis

The identification of a second oestrogen receptor (beta) has prompted a re-evaluation of the potential sites of action of oestrogens. The aim of the present study was to characterize immunoexpression of ER beta expression in the testis to complement earlier data which had demonstrated that expression of ER alpha is confined to testicular interstitial Leydig cells. In all testes studied, including those from both fetal (day 20.5 p.c.) and adult rats, ER beta was found to be expressed in multiple cell types. Sertoli cell nuclei were immunopositive at all ages. In adult testes expression in Sertoli cells was not stage dependent and was unaffected by ablation of Leydig cells. In fetal testes ER beta was also expressed in peritubular cells, fetal Leydig cells and gonocytes. In the pubertal and adult testis ER beta was detected in the nuclei of spermatogonia and most pachytene spermatocytes. Weak immunopositive staining was present in the cytoplasm of spermatocytes undergoing the second meiotic division. In conclusion the widespread expression of ER beta in the testis is consistent with a role for oestrogens in modulating spermatogenesis, and hence fertility, in the male.     

Accessories for breastfeeding; supplementary nutritional system for breastfeeding

Maternal breastfeeding is a physiological process which almost all women are capable of performing. Some special circumstances, such as the adoption of a baby, the problems a baby has sucking, or the temporary interruption of milk secretion, can cause difficulties and this is when the use of the so-called breastfeeding supplements is warranted. We describe the SNS supplementary nutritional system so that health professionals may understand its characteristics, use, and applications and therefore be able to offer women the necessary advise and assistance during breastfeeding.     

Production of inflammatory mediators and cytokine responsiveness of an SV40-transformed human proximal tubular epithelial cell line

PURPOSE: The clinical importance of the edge lift of rigid contact lenses is often neglected, possibly due to previous difficulties in its measurement. A new method of measuring axial edge lift (AEL) and radial edge lift (REL) using standard contact lens verification equipment, such as an optical spherometer, a thickness gauge, and contact lens V gauge, is described. METHODS: The technique was validated for trueness (accuracy) and precision (repeatability) by measuring the edge lift of a number of monocurve lenses, manufactured both with and without a normal edge finish. RESULTS: Edge lift was measured to an accuracy of 0.01 mm. CONCLUSIONS: As long as a mean of eight independent measurements of back optic zone radius (BOZR), sagitta, and one measurement of center thickness are taken, the pillar and collar technique is capable of producing accurate and repeatable measurements of the edge lift of a rigid contact lens.     

Reduced binding of immunoglobulin A (IgA) from patients with primary IgA nephropathy to the myeloid IgA Fc-receptor, CD89

BACKGROUND: Primary IgA nephropathy (IgAN) is associated with elevated levels of circulating IgA and is characterized by deposition of primarily IgA1 in the renal mesangium. It has not yet been clarified which mechanisms govern the deposition of IgA1 in the mesangium. One of the factors which may play a role in trapping of IgA in the mesangial area is the interaction of IgA with specific IgA receptors (Fc alphaR, CD89) on the mesangial cells. METHODS: In the present study IgA derived from patients with IgAN and controls was investigated for its interaction with human CD89, expressed on the surface of the murine B cell line IIA1.6. RESULTS: IgA binding to CD89 expressing cells was specific, concentration dependent and binding of dIgA and pIgA occurred in a more efficient fashion than that of mIgA. IgA binding to CD89 directly from serum of patients compared to controls showed no significant difference. However these experiments are affected by differences in IgA concentration and combinations of different sizes of IgA. Using purified fractions of mIgA, dIgA, and pIgA isolated from serum, a significantly reduced binding of mIgA to CD89 from patients compared to controls was observed. Finally, the binding of aIgA2 to CD89 was less inhibited using mIgA from patients with IgAN compared to controls. CONCLUSIONS: The reduced binding of mIgA to CD89 seems to contradict a direct role for CD89 in deposition of IgA. However reduced binding of mIgA to CD89 may affect IgA clearance, leading to higher serum IgA. Furthermore, since it has been demonstrated that mIgA can interfere with binding of di- and pIgA, CD89 could still contribute to pIgA deposition in the mesangial area.